ArticleAddiction science & clinical practice2022
Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study.
Article in Addiction science & clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial.Addiction (Abingdon, England) · 2026Trial
- Implementation Outcomes of Low Threshold Care for Persons with Opioid Use Disorders.Journal of general internal medicine · 2026Article
- "The alternative is they're not getting care at all": a qualitative interview study of opioid use disorder treatment providers' perspectives on quality and appropriateness of telehealth for buprenorphine access.Harm reduction journal · 2026Article
- "Trust and suspicion" client and provider perspectives on the acceptability of medication for opioid use disorder among people who inject drugs in Kampala, Uganda.Harm reduction journal · 2025Article
- Unmet Subsistence and Mental Health Needs in Women Experiencing Homelessness: Rethinking Care Models for Improved Outcomes.Journal of general internal medicine · 2025Article
- The impact of psychostimulant use on office based buprenorphine treatment retention.Harm reduction journal · 2025Article
- "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.Harm reduction journal · 2024Article
- Retention in Telehealth Treatment for Opioid Use Disorder Among Rural Populations: A Retrospective Cohort Study.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2023Article
- Typology of laws restricting access to methadone treatment in the United States: A latent class analysis.The International journal on drug policy · 2023Article
- Low-Threshold Buprenorphine in Non-Traditional Settings: A Scoping Review.Substance use : research and treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication for opioid use disorder (MOUD) reduces mortality, but few patients access MOUD. At a Federally Qualified Health Center (FQHC), we implemented a low barrier model of MOUD, including same-day MOUD initiation and a harm reduction philosophy.
objectiveTo investigate whether low barrier MOUD improved retention in care compared to traditional treatment. DESIGN AND
participantsRetrospective cohort study of patients with at least one visit seeking MOUD at the FQHC during a historical control period (3/1/2018-3/31/2019) and a low barrier intervention period (11/1/2019-7/31/2020). MAIN MEASURES: Primary outcomes were any MOUD prescription within 6 months of the index visit and 3- and 6-month retention in treatment without care gap, with care gap defined as 60 consecutive days without a visit or prescription. Secondary outcomes were all-cause hospitalization and emergency department visit within 6 months of the index visit. KEY
resultsBaseline characteristics were similar between the intervention (n = 113) and control (n = 90) groups, except the intervention group had higher rates of uninsured, public insurance and diabetes. Any MOUD prescription within 6 months of index visit was higher in the intervention group (97.3% vs 70%), with higher adjusted odds of MOUD prescription (OR = 4.01, 95% CI 2.08-7.71). Retention in care was similar between groups at 3 months (61.9% vs 60%, aOR = 1.06, 95% CI 0.78-1.44). At 6 months, a higher proportion of the intervention group was retained in care, but the difference was not statistically significant (53.1% vs 45.6%, aOR 1.27, 95% CI 0.93-1.73). There was no significant difference in adjusted odds of 6-month hospitalization or ED visit between groups.
conclusionsLow barrier MOUD engaged a higher risk population and did not result in any statistically significant difference in retention in care compared with a historical control. Future research should determine what interventions improve retention of patients engaged through low barrier care. Primary care clinics can implement low barrier treatment to make MOUD accessible to a broader population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.